Hepatitis B virus e antigen expression

乙型肝炎病毒e抗原表达

基本信息

  • 批准号:
    6722792
  • 负责人:
  • 金额:
    $ 7.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-04-01 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infects nearly 1/10th of the world population and causes severe liver diseases including cancer. The e antigen (HBeAg) is a secreted soluble protein that promotes immune tolerance during perinatal infection and buffers immunity against HBcAg. The corresponding anti-HBe immune response plays a critical role in the clearance of HBV infection. Therefore, following seroconversion from HBeAg antigenemia to anti-HBe, HBV escape mutants with reduced or no HBeAg production often replace wild-type HBV genomes. The core promoter mutants have various nucleotide changes around positions 1750 -1770 of the HBV genome, and the most common mutations at 1762 and 1764 are known to reduce HBeAg expression at the transcriptional level. The precore mutants have nonsense or frameshift mutations in the HBeAg coding sequence and terminate HBeAg expression at the translational level. Considering the critical importance of HBeAg and anti-HBe in shaping the outcome of HBV infection, we wish to uncover novel regulatory mechanisms for HBeAg expression. In this regard, perinatally infected South African patients seroconvert from HBeAg to anti-HBe at a much accelerated pace than similarly infected Asian patients. Interestingly, the South African HBV variants often harbor two or three point mutations near the precore initiation codon. We plan to verify whether the mutations cause leaky scanning to reduce HbeAg translation. Second, HBeAg maturation requires double proteolytic cleavage events in the secretory pathway. The first cleavage occurs in endoplasmic reticulum to remove the N-terminal signal peptide of 19 residues. A Val to Phe missense mutation at residue 17 is frequently detected in HBV genomes isolated from seroconverted patients. Since an aromatic residue at the -3 position of cleavage site is forbidden, we will test whether this mutation impairs HBeAg cleavage and secretion. Third, we recently identified several naturally occurring core promoter mutants with wild-type level of HBeAg production. Based on the results of preliminary mapping experiments, we will determine whether the number and position of core promoter mutations influence the level of HBeAg expression, and whether missense mutations in the HBeAg coding sequence also regulate HBeAg level. This study promises to verify and identify novel mechanisms regulating HBeAg expression, which has a major impact on the outcome of HBV infection.
描述(由申请人提供):B型肝炎病毒(HBV)感染了近1/10的世界人口,并导致严重的肝脏疾病,包括癌症。 e抗原(HBeAg)是一种分泌的可溶性蛋白,在围产期感染期间促进免疫耐受并缓冲针对HBcAg的免疫。 相应的抗HBe免疫应答在HBV感染的清除中起着关键作用。因此,在从HBeAg抗原血症血清转化为抗-HBe后,HBeAg产生减少或不产生的HBV逃逸突变体通常取代野生型HBV基因组。 核心启动子突变体在HBV基因组的1750 - 1770位置附近具有各种核苷酸变化,并且已知在1762和1764处的最常见突变在转录水平上降低HBeAg表达。 前C突变体在HBeAg编码序列中具有无义或移码突变,并在翻译水平上终止HBeAg表达。 考虑到HBeAg和抗-HBe在形成HBV感染结果中的关键重要性,我们希望揭示HBeAg表达的新调控机制。 在这方面,围产期感染的南非患者从HBeAg血清转化为抗-HBe的速度比类似感染的亚洲患者快得多。 有趣的是,南非的HBV变异体通常在前C起始密码子附近具有两个或三个点突变。 我们计划验证这些突变是否会导致漏扫描以减少HBeAg翻译。 其次,HBeAg成熟需要分泌途径中的双重蛋白水解裂解事件。 第一次切割发生在内质网中,以去除N端19个残基的信号肽。 在从血清转换患者分离的HBV基因组中经常检测到残基17处的瓦尔至Phe错义突变。 由于切割位点-3位的芳香残基是禁止的,我们将测试该突变是否会损害HBeAg的切割和分泌。 第三,我们最近发现了几个天然存在的核心启动子突变体与野生型水平的HBeAg生产。 基于初步定位实验的结果,我们将确定核心启动子突变的数量和位置是否影响HBeAg表达水平,以及HBeAg编码序列中的错义突变是否也调节HBeAg水平。 这项研究有望验证和确定新的机制调节HBeAg的表达,这对HBV感染的结果有重大影响。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hepatitis B Virus e Antigen Variants.
丙型肝炎病毒E抗原变体。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHUPING TONG其他文献

SHUPING TONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHUPING TONG', 18)}}的其他基金

Explore furin as an antiviral target to block hepatitis B virus e antigen production
探索弗林蛋白酶作为抗病毒靶点来阻断乙型肝炎病毒 e 抗原的产生
  • 批准号:
    10352854
  • 财政年份:
    2021
  • 资助金额:
    $ 7.7万
  • 项目类别:
Explore furin as an antiviral target to block hepatitis B virus e antigen production
探索弗林蛋白酶作为抗病毒靶点来阻断乙型肝炎病毒 e 抗原的产生
  • 批准号:
    10495261
  • 财政年份:
    2021
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus transcriptional interference and liver cancer-related mutations
乙型肝炎病毒转录干扰与肝癌相关突变
  • 批准号:
    9089897
  • 财政年份:
    2015
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus transcriptional interference and liver cancer-related mutations
乙型肝炎病毒转录干扰与肝癌相关突变
  • 批准号:
    8969082
  • 财政年份:
    2015
  • 资助金额:
    $ 7.7万
  • 项目类别:
2013 International Meeting on the Molecular Biology of Hepatitis B Viruses
2013年乙型肝炎病毒分子生物学国际会议
  • 批准号:
    8526887
  • 财政年份:
    2013
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus genotypes B and C
乙型肝炎病毒基因型 B 和 C
  • 批准号:
    8428335
  • 财政年份:
    2013
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus genotypes B and C
乙型肝炎病毒基因型 B 和 C
  • 批准号:
    8605164
  • 财政年份:
    2013
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus immune escape mutants
乙型肝炎病毒免疫逃逸突变体
  • 批准号:
    7585771
  • 财政年份:
    2008
  • 资助金额:
    $ 7.7万
  • 项目类别:
Hepatitis B virus immune escape mutants
乙型肝炎病毒免疫逃逸突变体
  • 批准号:
    7470857
  • 财政年份:
    2008
  • 资助金额:
    $ 7.7万
  • 项目类别:
Replication and secretion of hepatitis B virus variants
乙型肝炎病毒变异体的复制和分泌
  • 批准号:
    6557207
  • 财政年份:
    2003
  • 资助金额:
    $ 7.7万
  • 项目类别:

相似海外基金

The mechanism of oral carcinogenesis by FAT1 gene mutation
FAT1基因突变导致口腔癌的机制
  • 批准号:
    23K15977
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an efficient method combining quantum chemistry and machine learning to evolve PCR technology and gene mutation analysis
开发一种结合量子化学和机器学习的有效方法来发展 PCR 技术和基因突变分析
  • 批准号:
    22KJ2450
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of preemptive medicine for asymptomatic MEN1 gene mutation carriers
无症状MEN1基因突变携带者的抢先治疗药物开发
  • 批准号:
    23H03151
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidation of molecular mechanisms of occurrence of anaplastic thyroid cancer using gene mutation analysis and comprehensive gene expression analysis
利用基因突变分析和综合基因表达分析阐明甲状腺未分化癌发生的分子机制
  • 批准号:
    23K08067
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the molecular mechanism of maxillofacial hypoplasia caused by FAT1 gene mutation
FAT1基因突变引起颌面发育不全的分子机制阐明
  • 批准号:
    22K19629
  • 财政年份:
    2022
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Association between CD79B gene mutation and prognosis in vitreoretinal lymphoma
CD79B基因突变与玻璃体视网膜淋巴瘤预后的关系
  • 批准号:
    22K09763
  • 财政年份:
    2022
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene mutation/expression prediction from clinical images using artificial intelligence technology in pancreatic cancer
利用人工智能技术从临床图像预测胰腺癌基因突变/表达
  • 批准号:
    20K17570
  • 财政年份:
    2020
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of colorectal carcinogenesis mediated by PTPRK gene mutation
PTPRK基因突变介导的结直肠癌发生机制的阐明
  • 批准号:
    20K16311
  • 财政年份:
    2020
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the molecular mechanism of development of anaplastic thyroid cancer using gene mutation analysis and comprehensive gene expression analysis
利用基因突变分析和综合基因表达分析阐明甲状腺未分化癌发生的分子机制
  • 批准号:
    20K08953
  • 财政年份:
    2020
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of next-generation precision medicine targeting the pathways on which driver gene mutation-positive lung cancer depends
针对驱动基因突变阳性肺癌所依赖的途径开发下一代精准医疗
  • 批准号:
    20H03771
  • 财政年份:
    2020
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了